In accord with this idea, a recent study by Bardelli and colleagues (Germano et al. 2017) demonstrated that colorectal, breast, and pancreatic mouse cancer cell lines, where MMR was genetically inactivated, grew significantly slower when transplanted into immunocompetent mice compared with the isogenic MMR-proficient cancer cell lines, indicating rejection by the host immune system. Here, MRC1 is linked to cancer.